Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
DETER-SMM
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT03937635 ↗
- Recruiting
- ECOG-ACRIN Cancer Research Group
- Deep
We haven't built an HCP commentary report on DETER-SMM (daratumumab, dexamethasone and 1 more in Smoldering Plasma Cell Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DETER-SMM so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 624 | |
| Bluesky threads | 12 | |
| YouTube | 8 | |
| Podcasts | 3 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Daratumumab; Dexamethasone; Lenalidomide; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm I (daratumumab, lenalidomide, dexamethasone) · Experimental
- Arm II (lenalidomide, dexamethasone) · Experimental
- Enrollment
- 288 (estimated)
- Primary outcomes
- Overall survival (OS)
- Functional Assessment of Cancer Therapy-General (FACT-G) score
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Sep 16, 2019
- Primary completion
- Dec 31, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT03937635 · updated Aug 19, 2026